Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Clinical outcomes of patients with EBV-PTLD who fail rituximab following HSCT

Mohamad Mohty • 10 Jun 2022
EHA 2022
Lymphoma Rare Diseases Rituximab

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the clinical outcomes of patients with Epstein-Barr-positive post-transplant lymphoproliferative disorder (EBV-PTLD) who fail rituximab following hematopoietic stem cell transplantation (HSCT), outlining the potential of cytotoxic T-cell lymphocytes (CTLs) for the treatment of this rare condition. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Mohamad Mohty

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals